TG Therapeutics (TGTX) 10-Q 24 Jul 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 21, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'TGTX	'
Entity Common Stock, Shares Outstanding	'	38,120,655
Entity Registrant Name	'TG THERAPEUTICS, INC.	'
Entity Central Index Key	'0001001316	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$37,077,977	$40,485,466
Short-term investment securities	7,959,652	0
Interest receivable	74,682	27,169
Prepaid research and development	3,976,742	1,742,824
Other current assets	197,855	47,804
Total current assets	49,286,908	42,303,263
Long-term investment securities	6,110,309	4,918,897
Equipment, net	7,326	5,718
Goodwill	799,391	799,391
Other assets	98,365	85,121
Total assets	56,302,299	48,112,390
Current liabilities:	'	'
Notes payable, current portion	159,214	677,778
Accounts payable and accrued expenses	1,899,389	4,764,502
Accrued compensation	395,500	532,500
Current portion of deferred revenue	152,381	152,381
Interest payable	0	190,017
Total current liabilities	2,606,484	6,317,178
Deferred revenue, net of current portion	1,600,000	1,676,191
Notes payable, less current portion, at fair value	0	64,529
Total liabilities	4,206,484	8,057,898
Commitments and contingencies	'	'
Equity:	'	'
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 issued and outstanding as of June 30, 2014 and December 31, 2013)	0	0
Common stock, $0.001 par value per share (150,000,000 and 500,000,000 shares authorized, 38,161,964 and 34,336,235 shares issued, 38,120,655 and 34,294,926 shares outstanding at June 30, 2014 and December 31, 2013, respectively)	38,162	34,336
Contingently issuable shares	6	6
Additional paid-in capital	111,229,666	79,658,490
Treasury stock, at cost, 41,309 shares at June 30, 2014 and December 31, 2013	-234,337	-234,337
Accumulated deficit	-58,937,682	-39,404,003
Total equity	52,095,815	40,054,492
Total liabilities and equity	$56,302,299	$48,112,390

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	500,000,000
Common stock, shares issued	38,161,964	34,336,235
Common stock, shares outstanding	38,120,655	34,294,926
Treasury stock	41,309	41,309

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
License revenue	$38,095	$38,095	$76,190	$76,190
Research and development:	'	'	'	'
Noncash stock expense associated with in- licensing agreement	1,211,250	0	1,211,250	0
Noncash compensation	3,300,111	366,168	5,201,721	720,871
Other research and development	2,336,771	4,661,455	4,845,029	5,876,657
Total research and development	6,848,132	5,027,623	11,258,000	6,597,528
General and administrative:	'	'	'	'
Noncash compensation	4,438,735	1,007,600	6,768,563	2,538,374
Other general and administrative	706,725	631,637	1,610,249	1,283,094
Total general and administrative	5,145,460	1,639,237	8,378,812	3,821,468
Total costs and expenses	11,993,592	6,666,860	19,636,812	10,418,996
Operating loss	-11,955,497	-6,628,765	-19,560,622	-10,342,806
Other (income) expense:	'	'	'	'
Interest income	-12,727	-1,177	-26,201	-2,679
Other income	0	0	-95,427	0
Interest expense	234,787	240,014	461,127	471,486
Change in fair value of notes payable	-191,127	-283,050	-366,442	-553,450
Total other (income) expense	30,933	-44,213	-26,943	-84,643
Consolidated net loss	($11,986,430)	($6,584,552)	($19,533,679)	($10,258,163)
Basic and diluted net loss per common share (in dollars per share)	($0.36)	($0.29)	($0.62)	($0.46)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	32,985,130	22,483,394	31,546,060	22,213,335

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Share [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
	USD ($)	USD ($)	USD ($)		USD ($)	USD ($)	USD ($)
Balance at Dec. 31, 2013	$40,054,492	$0	$34,336	'	$79,658,490	($234,337)	($39,404,003)
Balance (in shares) at Dec. 31, 2013	'	0	34,336,235	6	'	41,309	'
Issuance of common stock in connection with exercise of warrants	1,602,060	'	700	'	1,601,360	'	'
Issuance of common stock in connection with exercise of warrants (in shares)	'	'	700,230	'	'	'	'
Issuance of restricted stock	0	'	298	'	-298	'	'
Issuance of restricted stock (in shares)	'	'	297,690	'	'	'	'
Issuance of common stock in public offering (net of offering costs of $1,344,440)	16,791,408	'	2,703	'	16,788,705	'	'
Issuance of common stock in public offering (net of offering costs of $1,344,440) (in shares)	'	'	2,702,809	'	'	'	'
Compensation in respect of restricted stock granted to employees, directors and consultants	11,970,284	'	'	'	11,970,284	'	'
Common stock issued in connection with in-licensing agreement	1,211,250	'	125	'	1,211,125	'	'
Common stock issued in connection with in-licensing agreement (in shares)	'	'	125,000	'	'	'	'
Net loss	-19,533,679	'	'	'	'	'	-19,533,679
Balance at Jun. 30, 2014	$52,095,815	$0	$38,162	'	$111,229,666	($234,337)	($58,937,682)
Balance (in shares) at Jun. 30, 2014	'	0	38,161,964	6	'	41,309	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Equity [Parenthetical] (USD $)	6 Months Ended
	Jun. 30, 2014
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$1,344,440

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Consolidated net loss	($19,533,679)	($10,258,163)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:	'	'
Gain on settlement of notes payable	-95,427	0
Noncash stock compensation expense	11,970,284	3,259,245
Noncash stock expense associated with in-licensing agreement	1,211,250	0
Depreciation	1,558	309
Amortization of premium on investment securities	66,943	0
Change in fair value of notes payable	94,685	-114,282
Changes in assets and liabilities:	'	'
(Increase) decrease in other current assets	-2,383,969	1,267,843
Increase in accrued interest receivable	-47,513	0
Increase in other assets	-13,244	-90,058
(Decrease) increase in accounts payable and accrued expenses	-3,002,113	1,217,871
(Decrease) increase in interest payable	-94,590	32,318
Decrease in deferred revenue	-76,191	-76,190
Net cash used in operating activities	-11,902,006	-4,761,107
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of equipment	-3,165	-1,672
Investment in held-to-maturity long-term securities	-6,127,539	'
Investment in held-to-maturity short-term securities	-3,090,469	0
Net cash used in investing activities	-9,221,173	-1,672
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from the exercise of warrants	1,602,060	1,723,736
Payment of notes payable	-677,778	0
Proceeds from sale of common stock, net	16,791,408	0
Net cash provided by financing activities	17,715,690	1,723,736
NET DECREASE IN CASH AND CASH EQUIVALENTS	-3,407,489	-3,039,043
Cash and cash equivalents at beginning of period	40,485,466	16,455,995
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$37,077,977	$13,416,952

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Description of Business
	We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for cancer and autoimmune diseases. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Currently, we are developing two therapies targeting hematological malignancies:
		⋅	TG-1101 (ublituximab) a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes; and
		⋅	TGR-1202, an orally available PI3K delta inhibitor.
	We are also developing a portfolio of inhibitors of IRAK-4 (interleukin-1 receptor-associated kinase 4), which is currently in pre-clinical development.
	The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
	Liquidity and Capital Resources
	We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of June 30, 2014, we have an accumulated deficit of $58,937,682.
	Our major sources of cash have been proceeds from the private placement and public offering of equity securities, the upfront payment from our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd. (“Ildong”), and warrant exercises. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.
	In March 2014, we raised approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million, in an underwritten public offering. See Note 5 for additional information.
	As of June 30, 2014, we had $51,222,620 in cash, cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately  24 months from June 30, 2014. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.
	Our Common Stock is quoted on the Nasdaq Capital Market and trades under the symbol “TGTX.”
	Recently Issued Accounting Standards
	In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for the Company beginning in fiscal 2017. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	On June 10, 2014, FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements. The update removes the definition of a development stage entity from FASB ASC 915 and eliminates the requirement for development stage entities to present inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The Company early adopted this standard for the period covered by the report herein.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.
	Cash and Cash Equivalents
	We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.
	Revenue Recognition
	We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
	Research and Development Costs
	Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.
	We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
	We recognize interest and penalties related to uncertain income tax positions in income tax expense.
	Stock-Based Compensation
	We recognize all share-based payments to employees and to non-employee directors as compensation for service as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.
	Basic and Diluted Net Income (Loss) Per Share of Common Stock
	Basic net income (loss) per share of Common Stock is calculated by dividing net income (loss) applicable to the Common Stock by the weighted-average number of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net income (loss) per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 9,702,633 and 10,114,847 at June 30, 2014 and 2013, respectively. During the three and six months ended June 30, 2014 and 2013, the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.
	Long-Lived Assets and Goodwill
	Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.
	Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH_AND_CASH_EQUIVALENTS

CASH AND CASH EQUIVALENTS	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents Disclosure [Text Block]	'
	NOTE 2 – CASH AND CASH EQUIVALENTS
		June 30, 2014		December 31, 2013
	Money market funds	$	6,361,558	$	554,069
	Checking and bank deposits		30,716,419		39,931,397
	Total	$	37,077,977	$	40,485,466

INVESTMENT_SECURITIES

INVESTMENT SECURITIES	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	NOTE 3 – INVESTMENT SECURITIES
	We record our investments as either held-to-maturity or available-for-sale. Held-to-maturity investments are recorded at amortized cost.
	The following tables summarize our investment securities at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Short-term investments:
	Obligations of domestic governmental agencies (maturing between January 2015 and June 2015) (held-to-maturity)	$	7,959,652	$	3,533	$	156	$	7,963,029
	Long-term investments:
	Obligations of domestic governmental agencies (maturing between July 2015 and September 2015) (held-to-maturity)	$	6,110,309	$	368	$	1,017	$	6,109,660
		December 31, 2013
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Long-term investments:
	Obligations of domestic governmental agencies (maturing between January 2015 and April 2015) (held-to-maturity)	$	4,918,897	$	—	$	650	$	4,918,247

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 4 – FAIR VALUE MEASUREMENTS
	We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
		·	Level 1 – quoted prices in active markets for identical assets and liabilities;
		·	Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and
		·	Level 3 – unobservable inputs that are not corroborated by market data.
	As of June 30, 2014 and December 31, 2013, the fair values of cash and cash equivalents, and notes and interest payable approximate their carrying value.
	Upon the merger between the Company (then known as Manhattan Pharmaceuticals, Inc., “Manhattan”) and Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances.  The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.  Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915.  The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.
	In connection with the reverse merger transaction (the “Exchange Transaction”) with TG Biologics, Inc. (“TGBio”) in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $18,614,000 at December 31, 2013 and $19,075,000 at June 30, 2014. As the 5% Notes are tied directly to net product cash flows derived from the preexisting products of Ariston, the 5% Notes and accrued interest were recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on the 5% Notes as of June 30, 2014.
	We elected the fair value option for valuing the 5% Notes upon the Exchange Transaction with TG Bio. We elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.
	As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of June 30, 2014 and December 31, 2013. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.
	The following table provides the fair value measurements of applicable financial liabilities as of June 30, 2014 and December 31, 2013:
			Financial liabilities at fair value
			as of June 30, 2014
			Level 1		Level 2		Level 3		Total
	5% Notes		$	—	$	—	$	159,214	$	159,214
	Totals		$	—	$	—	$	159,214	$	159,214
			Financial liabilities at fair value
			as of December 31, 2013
			Level 1		Level 2		Level 3		Total
	5% Notes		$	—	$	—	$	64,529	$	64,529
	Totals		$	—	$	—	$	64,529	$	64,529
	The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.
	The following table summarizes the changes in Level 3 instruments during the six months ended June 30, 2014:
	Fair value at December 31, 2013		$	64,529
	Interest accrued on face value of 5% Notes			461,127
	Change in fair value of Level 3 liabilities			-366,442
	Fair value at June 30, 2014		$	159,214
	The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statements of operations.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Shareholders Equity and Share-based Payments [Text Block]	'
	NOTE 5 - STOCKHOLDERS' EQUITY
	Preferred Stock
	Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.
	Common Stock
	Our amended and restated certificate of incorporation authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock. At the annual shareholder meeting on June 6, 2014, an amendment to the Company’s Certificate of Incorporation to decrease its authorized share capital by 350,000,000 shares from 500,000,000 to 150,000,000 was approved.
	On March 11, 2014, we announced the pricing of an underwritten sale of 2,702,809 shares of our Common Stock at a price of $6.71 per share for gross proceeds of approximately $18.1 million. Total net proceeds from this offering were approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-189015) that was previously filed and declared effective by the SEC on June 17, 2013.
	We currently have one shelf registration statement on Form S-3 filed and declared effective by the SEC (File No. 333-189015). Subsequent to the March 2014 offering, there remains available under this shelf registration statement up to approximately $117 million of Common Stock. We may offer the securities under our shelf registration statement from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that this shelf registration statement provides us with the flexibility to raise additional capital to finance our operations as needed.
	Equity Incentive Plans
	Shares available for the issuance of stock options or other stock-based awards under our stock option and incentive plans were 810,103 shares at June 30, 2014.
	Stock Options
	The following table summarizes stock option activity for the six months ended June 30, 2014:
		Number		Weighted-			Weighted-		Aggregate
		of shares		average			average		Intrinsic
				exercise price			Contractual		Value
							Term
							(in years)
	Outstanding at December 31, 2013	46,591		$	46.37		8.5		$	—
	Granted	—			—
	Exercised	—			—
	Forfeited	—			—
	Expired	-359			4,640.63
	Outstanding at June 30, 2014	46,232		$	10.7		8.07		$	229,540
	Vested and expected to vest at June 30, 2014	37,232		$	12.22		8.07		$	184,630
	Exercisable at June 30, 2014	37,232		$	12.22		8.07		$	184,630
	As of June 30, 2014, the total compensation cost related to unvested time-based option awards not yet recognized was $0. This amount does not include, as of June 30, 2014, 9,000 non-employee options outstanding which are milestone-based and vest upon certain corporate milestones. Stock-based compensation will be measured and recorded if and when a milestone occurs.
	Restricted Stock
	Certain employees, directors and consultants have been awarded restricted stock under the 2012 Incentive Plan. The restricted stock vesting consists of milestone and time-based vesting provisions. The following table summarizes restricted share activity for the six months ended June 30, 2014:
		Number of Shares		Weighted
				Average
				Grant Date
				Fair Value
	Outstanding at December 31, 2013	7,034,957		$	4.6
	Granted	297,690			8.14
	Vested	-502,124			6.88
	Forfeited	—			—
	Outstanding at June 30, 2014	6,830,523		$	4.65
	Total expense associated with restricted stock grants was $11,717,774 during the six months ended June 30, 2014. As of June 30, 2014, there was approximately $6,749,000 of total unrecognized compensation cost related to unvested time based restricted stock, which is expected to be recognized over a weighted-average period of 1.5 years. The unrecognized compensation cost does not include, as of June 30, 2014, 1,663,460 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,417,250 shares of restricted stock outstanding issued to non-employees. Milestone based noncash compensation expense will be measured and recorded if and when a milestone occurs.
	Warrants
	The following table summarizes warrant activity for the six months ended June 30, 2014:
		Warrants		Weighted-			Aggregate
				average			Intrinsic
				exercise price			Value
	Outstanding at December 31, 2013	5,718,947		$	1.34		$	14,809,030
	Issued	—			—
	Exercised	-700,230			2.29
	Expired	-9,795			20.92
	Outstanding at June 30, 2014	5,008,922		$	1.17		$	41,163,640
	Stock-Based Compensation
	The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the six months ended June 30, 2014.
	The following table summarizes stock-based compensation expense information about stock options and restricted stock for the three and six months ended June 30, 2014:
		Three months ended			Six months ended
		June 30, 2014			June 30, 2014
	Stock-based compensation expense associated with restricted stock	$	7,486,336		$	11,717,774
	Stock-based compensation expense associated with option grants		252,510			252,510
		$	7,738,846		$	11,970,284

NOTES_PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 6 – NOTES PAYABLE
	The following is a summary of notes payable:
		June 30, 2014						December 31, 2013
		Current		Non-		Total		Current		Non-		Total
		portion, net		current				portion, net		current
				portion,						portion,
				net						net
	Convertible 5% Notes Payable	$	159,214	$	-	$	159,214	$	-	$	64,529	$	64,529
	ICON Convertible Note		-		-		-		677,778		-		677,778
	Total	$	159,214	$	-	$	159,214	$	677,778	$	64,529	$	742,307
	We assumed the preceding notes payable as the result of the Exchange Transaction between the Company and TG Bio. Accordingly, a valuation using the guidance in the accounting literature for business combinations (ASC 805) was performed and these notes have been presented at their fair value on the date of the transaction.
	Convertible 5% Notes Payable
	On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub").  Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger.  As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.
	The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.  Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915.  We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which is March 8, 2015.
	In connection with the Exchange Transaction in December 2011, we performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $19,075,000 at June 30, 2014 and $18,614,000 at December 31, 2013. As the 5% Notes are tied directly to net product cash flows derived from the preexisting products of Ariston, the 5% Notes and accrued interest were recorded at fair value of $3,287,700 as of the date of the Exchange Transaction (See Note 4 for further details). No payments have been made on the 5% Notes as of June 30, 2014.
	ICON Convertible Note Payable
	As of December 31, 2013 the principal amount of the Amended ICON Note was $677,778, of which the entire balance had been classified as current and was reflected as notes payable, current portion, in the accompanying consolidated balance sheets. Interest payable on the Amended ICON Note was $190,017 as of December 31, 2013, and was reflected as interest payable in the accompanying consolidated balance sheets. In January 2014, we entered into a settlement and release agreement with ICON related to this note, under which we agreed to pay $772,369 in full settlement of the principal and interest due on this note, resulting in a gain of $95,427.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	6 Months Ended
	Jun. 30, 2014
License Agreement [Abstract]	'
License Agreement Disclosure [Text Block]	'
	NOTE 7 – LICENSE AGREEMENTS
	IRAK-4
	On June 23, 2014, we entered into an exclusive licensing agreement with Ligand Pharmaceuticals Incorporated ("Ligand") for the development and commercialization of Ligand's interleukin-1 receptor associated kinase-4 ("IRAK-4") inhibitor technology, which currently is in preclinical development for potential use against certain cancers and autoimmune diseases. IRAK-4 is a serine/threonine protein kinase that is a key downstream signaling component of the interleukin-1 receptor and multiple toll-like receptors.
	Under the terms of the license agreement, Ligand received 125,000 shares of our Common Stock as an upfront license fee. Ligand will also be eligible to receive maximum potential milestone payments of approximately $207 million upon the achievement of specific clinical, regulatory and commercial milestone events. Additionally, Ligand will be entitled to royalties on our future net sales of licensed products containing IRAK-4 inhibitors. The basic royalty rate for licensed products covered by Ligand's issued patents will be 6% for annual sales of up to $1 billion and 9.5% for annual sales in excess of that threshold.
	In connection with the license agreement, we recognized $1,211,250 of noncash research and development expense during the three months ended June 30, 2014 in connection with the issuance of the above mentioned Common Stock.
	Additionally, Opus Point Partners, LLC, who identified the opportunity and advised the Company on the transaction, will also be entitled to receive a 1% royalty for annual sales of up to $1 billion. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus Point Partners, LLC.
	TG-1101
	In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.
	An upfront payment of $2,000,000, which was received in December 2012, net of $330,000 of income tax withheld, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $76,000 for each of the six months ended June 30, 2014 and 2013, and, at June 30, 2014 and December 31, 2013, have deferred revenue of approximately $1,752,381 and $1,829,000, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified in current liabilities at June 30, 2014).
	We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 8 – RELATED PARTY TRANSACTIONS
	On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “License Agreement”). In connection with the License Agreement LFB Group was issued 5,000,000 shares of Common Stock, and a warrant to purchase 2,500,000 shares of Common Stock at a purchase price of $0.001 per share. In addition, on November 9, 2012, we nominated Dr. Yann Echelard to our Board of Directors as LFB Group’s nominee. LFB Group maintains the right to nominate a board member until such time as LFB Group owns less than 10% of the outstanding Common Stock.
	Under the terms of the License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred approximately $183,000 and $4,035,000 in expenses for such services during the six months ended June 30, 2014 and 2013, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of June 30, 2014 and December 31, 2013, we had approximately $760,000 and $1,745,000, respectively, recorded in accounts payable related to the License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of June 30, 2014 and December 31, 2013, we recorded $2,810,175 and $1,629,340, respectively, in prepaid research and development for such advance payments.
	In March 2014, we entered into a shared services agreement with Opus Point Partners Management, LLC (“Opus”) in which the parties agree to share a rented facility and costs for certain other services.  Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus. During the six months ended June 30, 2014, we incurred expenses of approximately $40,000, principally for rent, related to this agreement.
	As discussed in Note 7 above, in connection with the licensing agreement with Ligand Pharmaceuticals, Opus Point Partners, LLC, who identified the opportunity and advised the Company on the transaction, will be entitled to receive a 1% royalty for annual sales of up to $1 billion. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus Point Partners, LLC.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 9 – SUBSEQUENT EVENTS
	Stockholder Rights Plan
	On July 18, 2014, we adopted a stockholder rights plan. The stockholder rights plan is embodied in the Stockholder Protection Rights Agreement dated as of July 18, 2014 (the “Rights Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”).
	Accordingly, the Board of Directors declared a distribution of one right (a “Right”) for each outstanding share of the Common Stock, to stockholders of record at the close of business on July 28, 2014, for each share of Common Stock issued (including shares distributed from treasury) by the Company thereafter and prior to the Separation Time (as defined in the Rights Agreement), and for certain shares of Common Stock issued after the Separation Time. Following the Separation Time, each Right entitles the registered holder to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (the "Preferred Stock"), at a purchase price of $100.00 (the "Exercise Price"), subject to adjustment. The description and terms of the Rights are set forth in the Rights Agreement. Each one one-thousandth of a share of Preferred Stock has substantially the same rights as one share of Common Stock. Subject to the terms and conditions of the Rights Agreement, Rights become exercisable ten days after the public announcement that a “Person” has become an “Acquiring Person” (as each such term is defined in the Rights Agreement). Any Rights held by an Acquiring Person are void and may not be exercised.
	If a Person becomes an Acquiring Person, all holders of Rights, except the Acquiring Person, may purchase at the Right’s then-current exercise price, the Company’s common stock having a market value equal to twice the exercise price. Moreover, at any time after a Person becomes an Acquiring Person (unless such Person acquires 50 percent or more of the common stock of the Company then outstanding, as more fully described in the Rights Agreement), the Board of Directors may exchange all (but not less than all) of the then outstanding Rights (other than rights owned by such Person, which would have become void) for shares of Common Stock at an exchange ratio of one share of Common Stock per Right, appropriately adjusted in order to protect the interests of holders of Rights.
	The Rights Agreement was approved by our Board of Directors on July 18, 2014. The Rights will expire at the close of business on the ten year anniversary of the Date of Adoption, unless earlier exchanged or terminated by the Company.

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Business Description [Policy Text Block]	'
	Description of Business
	We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for cancer and autoimmune diseases. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Currently, we are developing two therapies targeting hematological malignancies:
		⋅	TG-1101 (ublituximab) a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes; and
		⋅	TGR-1202, an orally available PI3K delta inhibitor.
	We are also developing a portfolio of inhibitors of IRAK-4 (interleukin-1 receptor-associated kinase 4), which is currently in pre-clinical development.
	The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity and Capital Resources
	We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of June 30, 2014, we have an accumulated deficit of $58,937,682.
	Our major sources of cash have been proceeds from the private placement and public offering of equity securities, the upfront payment from our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd. (“Ildong”), and warrant exercises. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.
	In March 2014, we raised approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million, in an underwritten public offering. See Note 5 for additional information.
	As of June 30, 2014, we had $51,222,620 in cash, cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately  24 months from June 30, 2014. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.
	Our Common Stock is quoted on the Nasdaq Capital Market and trades under the symbol “TGTX.”
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Standards
	In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for the Company beginning in fiscal 2017. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	On June 10, 2014, FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements. The update removes the definition of a development stage entity from FASB ASC 915 and eliminates the requirement for development stage entities to present inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The Company early adopted this standard for the period covered by the report herein.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Costs
	Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.
	We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
	We recognize interest and penalties related to uncertain income tax positions in income tax expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	We recognize all share-based payments to employees and to non-employee directors as compensation for service as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.
Earnings Per Share, Policy [Policy Text Block]	'
	Basic and Diluted Net Income (Loss) Per Share of Common Stock
	Basic net income (loss) per share of Common Stock is calculated by dividing net income (loss) applicable to the Common Stock by the weighted-average number of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net income (loss) per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 9,702,633 and 10,114,847 at June 30, 2014 and 2013, respectively. During the three and six months ended June 30, 2014 and 2013, the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.
Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block]	'
	Long-Lived Assets and Goodwill
	Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.
	Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH_AND_CASH_EQUIVALENTS_Tabl

CASH AND CASH EQUIVALENTS (Tables)	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash and Cash Equivalents [Table Text Block]	'
		June 30, 2014		December 31, 2013
	Money market funds	$	6,361,558	$	554,069
	Checking and bank deposits		30,716,419		39,931,397
	Total	$	37,077,977	$	40,485,466

INVESTMENT_SECURITIES_Tables

INVESTMENT SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Held-to-maturity Securities [Table Text Block]	'
	The following tables summarize our investment securities at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Short-term investments:
	Obligations of domestic governmental agencies (maturing between January 2015 and June 2015) (held-to-maturity)	$	7,959,652	$	3,533	$	156	$	7,963,029
	Long-term investments:
	Obligations of domestic governmental agencies (maturing between July 2015 and September 2015) (held-to-maturity)	$	6,110,309	$	368	$	1,017	$	6,109,660
		December 31, 2013
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Long-term investments:
	Obligations of domestic governmental agencies (maturing between January 2015 and April 2015) (held-to-maturity)	$	4,918,897	$	—	$	650	$	4,918,247

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	'
	The following table provides the fair value measurements of applicable financial liabilities as of June 30, 2014 and December 31, 2013:
		Financial liabilities at fair value
		as of June 30, 2014
		Level 1		Level 2		Level 3		Total
	5% Notes	$	—	$	—	$	159,214	$	159,214
	Totals	$	—	$	—	$	159,214	$	159,214
		Financial liabilities at fair value
		as of December 31, 2013
		Level 1		Level 2		Level 3		Total
	5% Notes	$	—	$	—	$	64,529	$	64,529
	Totals	$	—	$	—	$	64,529	$	64,529
Change In Level Three Fair Value During Period [Table Text Block]	'
	The following table summarizes the changes in Level 3 instruments during the six months ended June 30, 2014:
	Fair value at December 31, 2013	$	64,529
	Interest accrued on face value of 5% Notes		461,127
	Change in fair value of Level 3 liabilities		-366,442
	Fair value at June 30, 2014	$	159,214

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes stock option activity for the six months ended June 30, 2014:
		Number		Weighted-			Weighted-		Aggregate
		of shares		average			average		Intrinsic
				exercise price			Contractual		Value
							Term
							(in years)
	Outstanding at December 31, 2013	46,591		$	46.37		8.5		$	—
	Granted	—			—
	Exercised	—			—
	Forfeited	—			—
	Expired	-359			4,640.63
	Outstanding at June 30, 2014	46,232		$	10.7		8.07		$	229,540
	Vested and expected to vest at June 30, 2014	37,232		$	12.22		8.07		$	184,630
	Exercisable at June 30, 2014	37,232		$	12.22		8.07		$	184,630
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	The following table summarizes restricted share activity for the six months ended June 30, 2014:
		Number of Shares		Weighted
				Average
				Grant Date
				Fair Value
	Outstanding at December 31, 2013	7,034,957		$	4.6
	Granted	297,690			8.14
	Vested	-502,124			6.88
	Forfeited	—			—
	Outstanding at June 30, 2014	6,830,523		$	4.65
Schedule Of Warrants Activity [Table Text Block]	'
	The following table summarizes warrant activity for the six months ended June 30, 2014:
		Warrants		Weighted-			Aggregate
				average			Intrinsic
				exercise price			Value
	Outstanding at December 31, 2013	5,718,947		$	1.34		$	14,809,030
	Issued	—			—
	Exercised	-700,230			2.29
	Expired	-9,795			20.92
	Outstanding at June 30, 2014	5,008,922		$	1.17		$	41,163,640
Schedule Of Share Based Compensation Expense [Text Block]	'
	The following table summarizes stock-based compensation expense information about stock options and restricted stock for the three and six months ended June 30, 2014:
		Three months ended			Six months ended
		June 30, 2014			June 30, 2014
	Stock-based compensation expense associated with restricted stock	$	7,486,336		$	11,717,774
	Stock-based compensation expense associated with option grants		252,510			252,510
		$	7,738,846		$	11,970,284

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	The following is a summary of notes payable:
		June 30, 2014						December 31, 2013
		Current		Non-		Total		Current		Non-		Total
		portion, net		current				portion, net		current
				portion,						portion,
				net						net
	Convertible 5% Notes Payable	$	159,214	$	-	$	159,214	$	-	$	64,529	$	64,529
	ICON Convertible Note		-		-		-		677,778		-		677,778
	Total	$	159,214	$	-	$	159,214	$	677,778	$	64,529	$	742,307

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	0 Months Ended	1 Months Ended	6 Months Ended
	Mar. 11, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Significant Accounting Policies [Line Items]	'	'	'	'	'
Accumulated deficit	'	'	$58,937,682	'	$39,404,003
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	9,702,633	10,114,847	'
Period Anticipated Sufficient To Fund Operating Cash Flow	'	'	'24 months	'	'
Cash, Cash Equivalents, and Short-term Investments, Total	'	'	51,222,620	'	'
Cash Equivalents Maturity Period	'	'	'less than three months	'	'
Underwriting discounts and offering expenses	1,300,000	1,300,000	'	'	'
Net Proceeds From Issuance Of Common Stock	'	$16,800,000	'	'	'

CASH_AND_CASH_EQUIVALENTS_Deta

CASH AND CASH EQUIVALENTS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]	'	'	'	'
Money market funds	$6,361,558	$554,069	'	'
Checking and bank deposits	30,716,419	39,931,397	'	'
Total	$37,077,977	$40,485,466	$13,416,952	$16,455,995

INVESTMENT_SECURITIES_Details

INVESTMENT SECURITIES (Details) (US Government Agencies Debt Securities [Member], USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Short-term Investments [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Amortized cost, as adjusted	$7,959,652	'
Gross unrealized holding gains	3,533	'
Gross unrealized holding losses	156	'
Estimated fair value	7,963,029	'
Other Long-term Investments [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Amortized cost, as adjusted	6,110,309	4,918,897
Gross unrealized holding gains	368	0
Gross unrealized holding losses	1,017	650
Estimated fair value	$6,109,660	$4,918,247

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	$159,214	$64,529
Totals	159,214	64,529
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	159,214	64,529
Totals	$159,214	$64,529

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2014
Fair Value, Measurement Changes In Level 3 Instruments [Line Items]	'
Fair value at December 31, 2013	$64,529
Interest accrued on face value of 5% Notes	461,127
Change in fair value of Level 3 liabilities	-366,442
Fair value at June 30, 2014	$159,214

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2011	Mar. 31, 2010
				Manhattan and Ariston Pharmaceuticals Merger [Member]
Fair Value Measurement [Line Items]	'	'	'	'
Notes Issued	'	'	'	$15,452,793
Debt Instrument, Interest Rate, Effective Percentage	5.00%	5.00%	'	5.00%
Debt Instrument, Convertible, Conversion Price	'	'	'	$1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	'	'	'	50.00%
Long-term Debt, Gross	19,075,000	18,614,000	16,876,000	'
Debt Instrument, Fair Value Disclosure	'	'	$3,287,700	'
Debt Instrument, Term	'	'	'	'5 years

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Equity Incentive Plans Stock Option Activity [Line Items]	'	'
Number of shares, Outstanding Beginning Balance	46,591	'
Number of shares, Granted	0	'
Number of shares, Exercised	0	'
Number of shares, Forfeited	0	'
Number of shares, Expired	-359	'
Number of shares, Outstanding Ending Balance	46,232	46,591
Number of shares, Vested and expected to vest at June 30, 2014	37,232	'
Number of shares, Exercisable June 30, 2014	37,232	'
Weighted - average exercise price, Outstanding Beginning Balance	$46.37	'
Weighted - average exercise price, Granted	$0	'
Weighted - average exercise price, Exercised	$0	'
Weighted - average exercise price, Forfeited	$0	'
Weighted - average exercise price, Expired	$4,640.63	'
Weighted - average exercise price, Outstanding Ending Balance	$10.70	$46.37
Weighted - average exercise price, Vested and expected to vest at June 30, 2014	$12.22	'
Weighted - average exercise price, Exercisable at June 30, 2014	$12.22	'
Weighted - average Contractual Term, Outstanding at ending period	'8 years 25 days	'8 years 6 months
Weighted - average Contractual Term, Vested and expected to vest at June 30, 2014	'8 years 25 days	'
Weighted - average Contractual Term, Exercisable at June 30, 2014	'8 years 25 days	'
Aggregate Intrinsic Value, Outstanding Beginning Balance	$0	'
Aggregate Intrinsic Value, Outstanding Ending Balance	229,540	0
Aggregate Intrinsic Value, Vested and expected to vest at June 30, 2014	184,630	'
Aggregate Intrinsic Value, Exercisable at June 30, 2014	$184,630	'

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (Restricted Stock [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Restricted Stock [Member]	'
Equity Incentive Plans Restricted Stock Activity [Line Items]	'
Number of Shares, Outstanding at December 31, 2013	7,034,957
Number of Shares, Granted	297,690
Number of Shares, Vested	-502,124
Number of Shares, Forfeited	0
Number of Shares, Outstanding at June 30, 2014	6,830,523
Weighted Average Grant Date Fair Value, Outstanding at December 31, 2013	$4.60
Weighted Average Grant Date Fair Value, Granted	$8.14
Weighted Average Grant Date Fair Value, Vested	$6.88
Weighted Average Grant Date Fair Value, Forfeited	$0
Weighted Average Grant Date Fair Value, Outstanding at June 30, 2014	$4.65

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (USD $)	6 Months Ended
	Jun. 30, 2014
Equity Incentive Plans Warrant Activity [Line Items]	'
Warrants, Outstanding at December 31, 2013	5,718,947
Warrants, Issued	0
Warrants, Exercised	-700,230
Warrants, Expired	-9,795
Warrants, Outstanding at June 30, 2014	5,008,922
Weighted - average exercise price of Warrants, Outstanding at December 31, 2013	$1.34
Weighted - average exercise price of Warrants, Issued	$0
Weighted - average exercise price of Warrants, Exercised	$2.29
Weighted - average exercise price of Warrants, Expired	$20.92
Weighted - average exercise price of Warrants, Outstanding at June 30, 2014	$1.17
Aggregate Intrinsic Value of Warrants, Outstanding at December 31, 2013	$14,809,030
Aggregate Intrinsic Value of Warrants, Outstanding at June 30, 2014	$41,163,640

STOCKHOLDERS_EQUITY_Details_3

STOCKHOLDERS' EQUITY (Details 3) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	$7,738,846	$11,970,284	$3,259,245
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense associated with restricted stock	7,486,336	11,717,774	'
Employee Stock Option [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense associated with option grants	$252,510	$252,510	'

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS' EQUITY (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 11, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stockholders Equity [Line Items]	'	'	'	'	'	'
Preferred stock, shares authorized	'	'	10,000,000	10,000,000	'	10,000,000
Common Stock, Shares Authorized	'	'	150,000,000	150,000,000	'	500,000,000
Preferred stock, par value (in dollars per share)	'	'	$0.00	$0.00	'	$0.00
Common stock, par value (in dollars per share)	'	'	$0.00	$0.00	'	$0.00
Share Based Compensation Non Employee Stock Options Outstanding	'	'	9,000	9,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	'	'	46,232	46,232	'	46,591
Shares available from Shelf Registration Statement	'	'	'	$117,000,000	'	'
Stock Issued During Period, Shares, New Issues	2,702,809	'	'	'	'	'
Share Price	$6.71	'	'	'	'	'
Proceeds From Issuance Of Common Stock	18,100,000	'	'	'	'	'
Net Proceeds From Shares New Issues Over-Allotments	16,800,000	'	'	16,791,408	0	'
Underwriting discounts and offering expenses	1,300,000	1,300,000	'	'	'	'
Share-based Compensation, Total	'	'	7,738,846	11,970,284	3,259,245	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	'	'	0	0	'	'
Common Stock [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	2,702,809	'	'
Non Employee Restricted Stock [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	'	'	2,417,250	2,417,250	'	'
Corporate Milestone [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	'	'	1,663,460	1,663,460	'	'
Restricted Stock [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'	'	'	'1 year 6 months	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	6,749,000	6,749,000	'	'
Share-based Compensation, Total	'	'	'	$11,717,774	'	'
Equity Incentive Plans [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	810,103	810,103	'	'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	$159,214	$677,778
Notes payable, Non-current portion, net	0	64,529
Total	159,214	742,307
Convertible Notes [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	159,214	0
Notes payable, Non-current portion, net	0	64,529
Total	159,214	64,529
ICON Convertible Note [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	0	677,778
Notes payable, Non-current portion, net	0	0
Total	$0	$677,778

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2011	Mar. 08, 2010	Jan. 31, 2014	Jun. 30, 2014	Mar. 08, 2010
				Convertible Notes Payable [Member]	Icon Clinical Research [Member]	Icon Clinical Research [Member]	Ariston [Member]
Notes Payable [Line Items]	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	5.00%	5.00%
Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt	'	'	'	'	'	'	50.00%
Debt Instrument, Convertible, Conversion Price	'	'	'	$1,125	'	'	'
Long-term Debt, Gross	$19,075,000	$18,614,000	$16,876,000	'	'	'	'
Notes Payable, Current, Total	159,214	677,778	'	'	'	'	'
Interest Payable	'	190,017	'	'	'	'	'
Debt Instrument, Maturity Date	'	'	'	8-Mar-15	'	'	'
Debt Instrument Settlement Of Principal And Interest	'	'	'	'	772,369	'	'
Debt Instrument Gain On Settlement	'	'	'	'	95,427	'	'
Debt Instrument, Fair Value Disclosure	'	'	$3,287,700	'	'	'	'

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 30, 2012

Dec. 31, 2013

Jun. 23, 2014

Jun. 30, 2014

Jun. 23, 2014

Jun. 23, 2014

Jun. 23, 2014

Jun. 23, 2014

Jun. 30, 2014

Jun. 30, 2014

Ligand [Member]

Ligand [Member]

Ligand [Member]

Ligand [Member]

Opus Point Partners, Llc [Member]

Opus Point Partners, Llc [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

License Agreement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License revenue

$38,095

$38,095

$76,190

$76,190

'

'

'

'

'

'

'

'

'

'

Deferred Revenue

1,752,381

'

1,752,381

'

'

1,829,000

'

'

'

'

'

'

'

'

Additional Amount Receivable On Achievement Of Pre Specified Milestones

'

'

5,000,000,000

'

'

'

'

'

'

'

'

'

'

'

Income taxes

'

'

'

'

330,000

'

'

'

'

'

'

'

'

'

Business Acquisition Purchase Agreement Period Description

'

'

'license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Fees Received

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

'

'

'

'

'

125,000

'

'

'

'

'

'

Non Cash Stock Expense

1,211,250

0

1,211,250

0

'

'

'

'

'

'

'

'

1,211,250

1,211,250

Maximum Potential Payments Payable

'

'

'

'

'

'

207,000,000

'

'

'

'

'

'

'

Royalty payment Effective Percentage

'

'

'

'

'

'

'

'

9.50%

6.00%

1.00%

'

'

'

Maximum sales for royalty expense

'

'

'

'

'

'

'

'

1,000,000,000

'

'

1,000,000,000

'

'

Accounts and Other Receivables, Net, Current

$152,000

'

$152,000

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended			6 Months Ended	1 Months Ended	6 Months Ended
	Mar. 11, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Jan. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
							Opus [Member]	LFB Group [Member]	LFB Group [Member]	LFB Group [Member]	LFB Group [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	2,702,809	'	'	'	'	'	'	5,000,000	'	'	'
Other research and development	'	$2,336,771	$4,661,455	$4,845,029	$5,876,657	'	'	'	$183,000	$4,035,000	'
Accounts Payable	'	'	'	'	'	'	'	'	760,000	'	1,745,000
Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants	'	'	'	'	'	'	'	2,500,000	'	'	'
Common Stock Purchase Price Per Share	'	'	'	'	'	'	'	$0.00	'	'	'
Costs and Expenses, Related Party	'	'	'	'	'	'	40,000	'	'	'	'
Prepaid Research And Development	'	$3,976,742	'	$3,976,742	'	$1,742,824	'	'	$2,810,175	'	$1,629,340
Royalty Revenue Description	'	'	'	'	'	'	'Opus Point Partners, LLC, who identified the opportunity and advised the Company on the transaction, will be entitled to receive a 1% royalty for annual sales of up to $1 billion.	'	'	'	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jul. 28, 2014
			Subsequent Event [Member]
			Series A Participating Preferred Stock [Member]
Subsequent Event [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Description	'	'	'Following the Separation Time, each Right entitles the registered holder to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (the "Preferred Stock"), at a purchase price of $100.00 (the "Exercise Price"), subject to adjustment.
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00	$0.00
Investment Options, Exercise Price	'	'	$100